keyword
MENU ▼
Read by QxMD icon Read
search

baclofen AND alcohol

keyword
https://www.readbyqxmd.com/read/29224234/an-observational-study-of-benzodiazepine-prescription-during-inpatient-alcohol-detoxification-for-patients-with-versus-without-chronic-pretreatment-with-high-dosage-baclofen
#1
Laura Martinez, Florence Vorspan, Xavier Declèves, Julien Azuar, Maeva Fortias, Franck Questel, Alexandra Dereux, Leslie Grichy, Hélène Barreteau, Frank Bellivier, Jean-Pierre Lépine, Vanessa Bloch
High dose baclofen is prescribed as a maintenance treatment to reduce alcohol use in patients with alcohol use disorder. Nevertheless, some patients still have massive alcohol intakes and require inpatient alcohol withdrawal. AIM: to compare the oral dose of benzodiazepine prescribed to manage alcohol withdrawal symptoms in patients with versus without steady state pre-treatment with high dose baclofen. METHODS: Retrospective chart review study. Prescribed benzodiazepine dose expressed in diazepam-equivalent was compared between groups...
December 10, 2017: Fundamental & Clinical Pharmacology
https://www.readbyqxmd.com/read/29143356/on-the-ground-application-of-the-temporary-recommendation-for-use-regulatory-measure-on-off-label-use-of-baclofen-for-alcohol-dependence-in-france-a-regional-survey-of-community-pharmacies
#2
Marine Auffret, Benjamin Rolland, Anne-Sylvie Caous, Louise Gaboriau, Sylvie Deheul, Régis Bordet, Sophie Gautier
The "temporary recommendation for use" (TRU) is a French novel regulatory measure for off-label drug. The first TRU to be issued by the French drug agency (in March 2014) pertained to the off-label use of baclofen for alcohol dependence (AD). We performed a questionnaire-based survey of the on-the-ground application of the baclofen TRU among community pharmacies in northern France. A pharmacist from 70 of the 219 pharmacies contacted (response rate: 32.0%) completed the questionnaire. The mean ± standard deviation number of off-label baclofen prescriptions for AD was 2...
November 15, 2017: Fundamental & Clinical Pharmacology
https://www.readbyqxmd.com/read/29120249/alcohol-addiction-the-safety-of-available-approved-treatment-options
#3
Mariangela Antonelli, Anna Ferrulli, Luisa Sestito, Gabriele A Vassallo, Claudia Tarli, Carolina Mosoni, Maria M Rando, Antonio Mirijello, Antonio Gasbarrini, Giovanni Addolorato
Alcohol Use Disorder (AUD) is a leading cause of mortality and morbidity worldwide. At present disulfiram, naltrexone and acamprosate are approved for the treatment of AUD in U.S. and Europe. Nalmefene is approved in Europe and sodium oxybate is approved in Italy and Austria only. Baclofen received a "temporary recommendation for use" in France. Areas covered. The safety of the medications mentioned above on liver, digestive system, kidney function, nervous system, pregnancy and lactation and their possible side effects are described and discussed...
November 9, 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/29091319/population-pharmacokinetics-of-oral-baclofen-at-steady-state-in-alcoholic-dependent-adult-patients
#4
Lucie Chevillard, Naomi Sabo, Michel Tod, Laurence Labat, Céline Chasport, Céline Chevaleyre, Florence Thibaut, Jérôme Barré, Julien Azuar, Franck Questel, Florence Vorspan, Vanessa Bloch, Frank Bellivier, Bernard Granger, Camille Barrault, Xavier Declèves
Baclofen has been proposed for few years to help treating alcohol-dependence at higher doses than those used in neurology. Baclofen pharmacokinetics has been previously well described at low oral or intravenous doses but remains poorly investigated with such high oral doses. We here describe dose regimens of baclofen in 143 alcohol-dependent-patients treated with steady-state oral doses of baclofen. Plasma baclofen levels were measured in blood samples using liquid chromatography coupled with tandem mass spectrometry...
November 1, 2017: Fundamental & Clinical Pharmacology
https://www.readbyqxmd.com/read/29050951/microinjection-of-baclofen-and-cgp7930-into-the-ventral-tegmental-area-suppresses-alcohol-self-administration-in-alcohol-preferring-rats
#5
REVIEW
Paola Maccioni, Irene Lorrai, Andrea Contini, Kimberly Leite-Morris, Giancarlo Colombo
Systemic administration of the orthosteric agonist, baclofen, and several positive allosteric modulators (PAMs) of the GABAB receptor has repeatedly been reported to decrease operant oral alcohol self-administration in rats. The aim of the present study was to evaluate the contribution of the mesolimbic dopamine system to the reducing effect of baclofen and GABAB PAMs on the reinforcing properties of alcohol. To this end, baclofen or the GABAB PAM CGP7930 were microinjected into the ventral tegmental area (VTA) of selectively bred, Sardinian alcohol-preferring (sP) rats trained to self-administer alcohol...
October 16, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/29036310/baclofen-self-poisoning-in-the-era-of-changing-indication-multicentric-reports-to-a-french-poison-control-centre
#6
Maxime Léger, Marion Brunet, Gaël Le Roux, Nicolas Lerolle, David Boels
Aims: Baclofen has gained interest in treating alcohol use disorder patients. These patients are at risk of voluntary drug intoxications. Understanding the context of baclofen's widespread use for alcohol use disorder, a recent evaluation of the epidemiology, morbidity and mortality of baclofen self-poisoning episodes is necessary. Methods: All baclofen self-poisoning reported to the Western France Poison Control Centre between January 2008 and December 2015 were included for analysis in this retrospective study...
September 28, 2017: Alcohol and Alcoholism: International Journal of the Medical Council on Alcoholism
https://www.readbyqxmd.com/read/28967184/lc-ms-ms-method-for-quantification-of-baclofen-in-hair-a-useful-tool-to-assess-compliance-in-alcohol-dependent-patients
#7
I A Larabi, N Fabresse, A Knapp, M Forcet, F J Baud, G Lorin Grandmaison, J C Alvarez
In order to evaluate adherence to treatment, we developed and validated a novel LC-MS/MS method for baclofen quantification in hair. 20 mg were washed twice with dichloromethane, incubated in phosphate buffer (pH 5) for 10 min at 95°C, then extracted by liquid-liquid extraction in alkaline condition. Baclofen-d4 was used as internal standard. This method was applied to assess compliance in four treated alcohol dependent patients (3 dead and one alive). Blood quantification of baclofen and ethanol were performed in the 4 cases...
October 2, 2017: Drug Testing and Analysis
https://www.readbyqxmd.com/read/28940866/pharmacologically-controlled-drinking-in-the-treatment-of-alcohol-dependence-or-alcohol-use-disorders-a-systematic-review-with-direct-and-network-meta-analyses-on-nalmefene-naltrexone-acamprosate-baclofen-and-topiramate
#8
REVIEW
Clément Palpacuer, Renan Duprez, Alexandre Huneau, Clara Locher, Rémy Boussageon, Bruno Laviolle, Florian Naudet
BACKGROUND AND AIMS: Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders (AUDs) is an emerging concept. Our objective was to explore the comparative effectiveness of drugs used in this indication. DESIGN: Systematic review with direct and network meta-analysis of double-blind randomized controlled trials (RCTs) assessing the efficacy of nalmefene, naltrexone, acamprosate, baclofen or topiramate in non-abstinent adults diagnosed with alcohol dependence or AUDs...
September 20, 2017: Addiction
https://www.readbyqxmd.com/read/28939163/systematic-review-baclofen-dosing-protocols-for-alcohol-use-disorders-used-in-observational-studies
#9
REVIEW
Andrew Thompson, Lynn Owens, Paul Richardson, Munir Pirmohamed
The popularity of baclofen as an anti-craving agent in the treatment of alcohol use disorders (AUDs) has increased, especially in patients with established liver disease. However, evidence-based guidelines to inform practice are lacking. The aim of this systematic review is explore the prescribing practices of baclofen in AUD treatment. Electronic databases were searched for relevant articles from 2002. Assessment of eligibility criteria for inclusion was performed independently by two investigators. The main outcomes of interest were maximum dose, starting dose, titration regimen, effectiveness, and tolerability...
September 19, 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28919445/cognitive-effects-of-labeled-addictolytic-medications
#10
REVIEW
Camille Noélie Pujol, Cecilia Paasche, Vincent Laprevote, Benoit Trojak, Pierre Vidailhet, Elisabeth Bacon, Laurence Lalanne
INTRODUCTION: Alcohol, tobacco, and illegal drug usage is pervasive throughout the world, and abuse of these substances is a major contributor to the global disease burden. Many pharmacotherapies have been developed over the last 50years to target addictive disorders. While the efficacy of these pharmacotherapies is largely recognized, their cognitive impact is less known. However, all substance abuse disorders are known to promote cognitive disorders like executive dysfunction and memory impairment...
September 14, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28827047/high-drinking-in-the-dark-hdid-mice-are-sensitive-to-the-effects-of-some-clinically-relevant-drugs-to-reduce-binge-like-drinking
#11
John C Crabbe, Angela R Ozburn, Pamela Metten, Amanda Barkley-Levenson, Jason P Schlumbohm, Stephanie E Spence, Wyatt R Hack, Lawrence C Huang
BACKGROUND: There is a serious public health need for better understanding of alcohol use disorder disease mechanisms and for improved treatments. At this writing, only three drugs are approved by the Food and Drug Administration as medications to treat alcohol use disorders - disulfiram, naltrexone, and acamprosate. Binge drinking is a form of abusive alcohol drinking defined by the NIAAA as a drinking to blood alcohol levels (BALs)>0.08% during a period of approximately 2h. To model genetic risk for binge-like drinking, we have used selective breeding to create a unique animal model, High Drinking in the Dark (HDID) mice...
September 2017: Pharmacology, Biochemistry, and Behavior
https://www.readbyqxmd.com/read/28822350/baclofen-for-alcohol-withdrawal
#12
REVIEW
Jia Liu, Lu-Ning Wang
BACKGROUND: Baclofen shows potential for rapidly reducing symptoms of severe alcohol withdrawal syndrome (AWS) in people with alcoholism. Treatment with baclofen is easy to manage and rarely produces euphoria or other pleasant effects, or craving for the drug. This is an updated version of the original Cochrane Review published in 2015, Issue 4. OBJECTIVES: To assess the efficacy and safety of baclofen for people with AWS. SEARCH METHODS: We updated our searches of the following databases to March 2017: the Cochrane Drugs and Alcohol Group Specialised Register, CENTRAL, PubMed, Embase, and CINAHL...
August 20, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28755747/a-prospective-cohort-study-examining-the-effectiveness-of-baclofen-in-the-maintenance-of-abstinence-in-alcohol-use-disorder-patients-attending-a-joint-liver-and-alcohol-treatment-clinic
#13
Lynn Owens, Andrew Thompson, Abi Rose, Ian Gilmore, Munir Pirmohamed, Paul Richardson
OBJECTIVE: Alcohol-related liver disease (ARLD) is the leading cause of alcohol-related mortality in the UK. Helping patients with ARLD to stop drinking is an important treatment goal. The aim of this study is to explore baclofen's utility in maintaining abstinence. METHODS - A PROSPECTIVE COHORT STUDY: Patients with ARLD were commenced on baclofen; the dose was titrated according to tolerability and response up to 30 mg three times daily. Severity of physical dependence and biochemical markers of liver injury were assessed at baseline, 3 months, and 12 months...
August 2017: Alcohol
https://www.readbyqxmd.com/read/28753481/baclofen-and-naltrexone-effects-on-alcohol-self-administration-comparison-of-treatment-initiated-during-abstinence-or-ongoing-alcohol-access-in-baboons
#14
August F Holtyn, Barbara J Kaminski, Elise M Weerts
BACKGROUND: Baclofen, a GABAB receptor agonist, is under investigation as a pharmacotherapy for alcohol use disorder. Treatment with a pharmacotherapeutic can be initiated during alcohol abstinence or active drinking, which may influence treatment outcomes. This study examined whether baclofen treatment initiated and maintained during alcohol abstinence would reduce alcohol seeking and self-administration upon return to alcohol access, and whether effects differed from treatment initiated and maintained during ongoing alcohol access...
October 1, 2017: Drug and Alcohol Dependence
https://www.readbyqxmd.com/read/28727631/one-year-of-baclofen-in-100-patients-with-or-without-cirrhosis-a-french-real-life-experience
#15
Camille Barrault, Hortensia Lison, Françoise Roudot-Thoraval, Armand Garioud, Charlotte Costentin, Véronique Béhar, Mourad Medmoun, Georges Pulwermacher, Hervé Hagège, Jean-François Cadranel
BACKGROUND: Several studies have suggested the efficacy of baclofen in reducing alcohol consumption, leading to a temporary recommendation for use in France. AIM: Our aim was to report our experience in using baclofen in alcohol-dependant patients with or without liver cirrhosis. PATIENTS AND METHODS: Consecutive patients from two liver and alcohol units were recruited over a 3-year period and received increasing doses of baclofen associated with social, psychological, and medical care...
October 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28658981/pharmacotherapy-of-alcoholism-an-update-on-approved-and-off-label-medications
#16
REVIEW
Michael Soyka, Christian A Müller
Only a few medications are available for the treatment of alcohol use disorders (AUDs). Areas covered: This paper discusses approved AUD medications, including the opioid antagonists naltrexone and nalmefene (the latter is licensed for reduction of alcohol consumption only), the putative glutamate receptor antagonist acamprosate and the aldehyde dehydrogenase inhibitor disulfiram. It also covers off-label medications of interest, including topiramate, gabapentin, ondansetron, varenicline, baclofen, sodium oxybate and antidepressants...
August 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28525555/a-randomized-placebo-controlled-study-of-high-dose-baclofen-in-alcohol-dependent-patients-the-alpadir-study
#17
Michel Reynaud, Henri-Jean Aubin, Francoise Trinquet, Benjamin Zakine, Corinne Dano, Maurice Dematteis, Benoit Trojak, Francois Paille, Michel Detilleux
Aims: Alcohol dependence is a major public health issue with a need for new pharmacological treatments. The ALPADIR study assessed the efficacy and safety of baclofen at the target dose of 180 mg/day for the maintenance of abstinence and the reduction in alcohol consumption in alcohol-dependent patients. Methods: Three hundred and twenty adult patients (158 baclofen and 162 placebo) were randomized after alcohol detoxification. After a 7-week titration, the maintenance dose was provided for 17 weeks, then progressively decreased over 2 weeks before stopping...
July 1, 2017: Alcohol and Alcoholism: International Journal of the Medical Council on Alcoholism
https://www.readbyqxmd.com/read/28517239/the-dose-effect-relationship-of-baclofen-in-alcohol-dependence-a-1-year-cohort-study
#18
Baptiste Pignon, Julien Labreuche, Marine Auffret, Sophie Gautier, Sylvie Deheul, Nicolas Simioni, Olivier Cottencin, Régis Bordet, Alain Duhamel, Benjamin Rolland
OBJECTIVE: Our aim is to study the relationship between dose of baclofen and effectiveness in alcohol dependence. METHODS: Two hundred two patients with alcohol dependence, who received baclofen treatment for drinking reduction, were followed up for 1 year. For each patient-month of treatment, the maximum daily dose of baclofen (DDB) and average weekly alcohol consumption (AWAC) were calculated. We defined a favorable drinking outcome as an AWAC under 200 g/w for at least 2 consecutive months...
May 18, 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28495786/speaking-fluently-with-baclofen
#19
Esther Beraha, Pieter Bodewits, Wim van den Brink, Reinout Wiers
Baclofen is a new and promising pharmacological compound for the treatment of alcohol dependence (AD). Although several randomised trials found a reduction of craving and higher abstinence rates with low and high doses of baclofen, others failed to show positive effects. In this case study, the successful treatment of a patient with AD with daily 120 mg of baclofen is described. In addition to a decrease in alcohol use, we observed the cessation of stuttering during treatment with baclofen, reoccurrence of stuttering following discontinuation, and cessation of stuttering after reinstatement of the treatment...
May 11, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28449569/baclofen-abuse-due-to-its-hypomanic-effect-in-patients-with-alcohol-dependence-and-comorbid-major-depressive-disorder
#20
Soumitra Ghosh, Dhrubajyoti Bhuyan
Baclofen is a gamma-aminobutyric acid type B receptor agonist used as an anti-craving agent for treatment of alcohol dependence. It has gained popularity in the recent times because it is well tolerated even in patients with hepatic impairments. Herein we are summarizing the latest literature about baclofen induced hypomania and are reporting a case of baclofen abuse because of its mood elevating property in a patient of alcohol dependence with comorbid major depressive disorder. Literature review and case study of a 36-year-old male with alcohol dependence with comorbid major depressive disorder was prescribed with tablet baclofen as an anti-craving agent along with antidepressant medicines...
May 31, 2017: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
keyword
keyword
86358
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"